论文部分内容阅读
目的:探讨神经节苷脂钠治疗急性脑梗死患者的疗效及对其血清高敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)的影响。方法:急性脑梗死患者216例随机分为观察组与对照组,每组108例。对照组患者予常规治疗,观察组患者在对照组基础上加用神经节苷脂注射液100 mg加入0.9%氯化钠注射液250 ml,ivd,qd。两组疗程均为14 d。评价两组临床疗效,比较两组患者治疗前后神经功能缺损程度评分(NDS)、日常生活活动量评分,以及血清hs-CRP和TNF-α水平变化。观察两组药品不良反应发生情况。结果:观察组治疗总有效率为90.7%,明显高于对照组的71.3%(P<0.05)。治疗后,观察组NDS评分较前明显降低,而ADL评分较前明显提高(P<0.05),且与对照组比较,差异均有统计学意义(P<0.05);而对照组患者治疗前后NDS及ADL评分无明显变化(P>0.05)。两组患者治疗后血清hs-CRP和TNF-α水平均较治疗前明显降低(P<0.05),且观察组血清hs-CRP和TNF-α水平明显低于对照组(P<0.05)。治疗期间两组患者均未见药品不良反应发生。结论:神经节苷脂钠辅助治疗急性脑梗死疗效良好,能显著降低患者血清hs-CRP和TNF-α水平,改善患者NDS及ADL评分,且安全性好,值得在临床上进一步推广应用。
Objective: To investigate the therapeutic effect of ganglioside sodium in patients with acute cerebral infarction and its effect on serum hs-CRP and TNF-α. Methods: 216 patients with acute cerebral infarction were randomly divided into observation group and control group, 108 cases in each group. Patients in the control group were given routine treatment. The patients in the observation group were treated with ganglioside injection 100 mg and 0.9% sodium chloride injection 250 ml, ivd, qd on the basis of the control group. The two courses of treatment were 14 d. The clinical efficacy of the two groups were evaluated. The scores of NDS, activities of daily living and serum levels of hs-CRP and TNF-α before and after treatment were compared between the two groups. Two groups of adverse drug reactions were observed. Results: The total effective rate of the observation group was 90.7%, which was significantly higher than that of the control group (71.3%, P <0.05). After treatment, the score of NDS in the observation group was significantly lower than that of the former group, while the ADL score was significantly increased (P <0.05), and the difference was statistically significant compared with the control group (P <0.05) And ADL score no significant change (P> 0.05). The serum levels of hs-CRP and TNF-α in both groups were significantly lower than those before treatment (P <0.05), and the levels of hs-CRP and TNF-α in the observation group were significantly lower than those in the control group (P <0.05). During the treatment of two groups of patients showed no adverse drug reactions. Conclusion: Ganglioside adjuvant treatment of acute cerebral infarction with good effect, can significantly reduce the serum hs-CRP and TNF-α levels, improve patients with NDS and ADL score, and good safety, it is worth further clinical application.